Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 06/7/13 → 03/17/15 |
Funding
- National Cancer Institute: $1.00
A Randomized Phase II Trial of Erlotinib, Cabozantinib, or Erlotinib plus Cabozantinib as 2nd or 3rd Line Therapy in Patients with EGFR Wild-Type NSCLC
- Keresztes, Roger (PI)
- Kudelka, Andrzej (CoPI)
Project: Research